循环微小RNA(miRNA)是用于癌症检测的有前景的生物标志物。然而,缺乏非小细胞肺癌(NSCLC)的多种族和多中心研究.我们招募了221名NSCLC患者,来自中国和美国的161个对照和56个良性结节。使用TaqMan低密度阵列进行初始miRNA筛选,然后通过RT-qPCR在中国队列中单独确认。最后,我们进行了一项来自美国队列的盲试验,以验证我们的发现.RT-qPCR证实miR-483-5p,miR-193a-3p,与对照组相比,患者的miR-25、miR-214和miR-7显著升高。这五个血清miRNA组的ROC曲线的曲线下面积(AUC)为0.976(95%CI,0.939-1.0;P<0.0001)和0.823(95%CI,0.75-0.896;P<0.0001),分别。在盲目的审判中,该小组对美国队列中95%的NSCLC病例和84%的对照进行了正确分类.最重要的是,该小组能够区分NSCLC和良性结节,在美国队列中AUC为0.979(95%CI,0.959-1.0),并允许正确预测中国和美国队列中86%和95%的I-II期肿瘤,分别。该血清miRNA组具有诊断种族不同的NSCLC患者的潜力。
Circulating microRNAs (miRNAs) are promising biomarkers for cancer detection. However, multiethnic and multicentric studies of non-small-cell lung cancer (NSCLC) are lacking. We recruited 221 NSCLC patients, 161 controls and 56 benign nodules from both China and America. Initial miRNA screening was performed using the TaqMan Low Density Array followed by confirming individually by RT-qPCR in Chinese cohorts. Finally, we performed a blind
trial from an American cohort to validate our findings. RT-qPCR confirmed that miR-483-5p, miR-193a-3p, miR-25, miR-214 and miR-7 were significantly elevated in patients compared to controls. The areas under the curve (AUCs) of the ROC curve of this five-serum miRNA panel were 0.976 (95% CI, 0.939-1.0; P < 0.0001) and 0.823 (95% CI, 0.75-0.896; P < 0.0001) for the two confirmation sets, respectively. In the blind
trial, the panel correctly classified 95% NSCLC cases and 84% controls from the American cohort. Most importantly, the panel was capable of distinguishing NSCLC from benign nodules with an AUC of 0.979 (95% CI, 0.959-1.0) in the American cohort and allowed correct prediction of 86% and 95% stage I-II tumors in the Chinese and American cohorts, respectively. This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients.